FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111960933> ?p ?o ?g. }

• W3111960933 abstract "Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in HD patients. Methods One hundred and thirty-three patients HD on cinacalcet were screened, and 93 patients with serum-intact parathyroid hormone (iPTH) level of ≥ 60 pg/mL and serum albumin-corrected calcium (cCa) level of ≥ 8.4 mg/dL were enrolled. The patients were divided into three groups based on the dose of cinacalcet (i.e., 25, 50, and ≥ 75 mg) and switched to etelcalcetide. Etelcalcetide was administered three times per week for 24 weeks. The primary and secondary endpoints were etelcalcetide conversion dose and etelcalcetide effectiveness for iPTH levels (target range: 60–240 pg/mL), respectively. Results Of the 68 patients whose iPTH level was within the management target at screening, 60 patients maintained the target level at the end of the study. Among patients whose iPTH level exceeded 240 pg/mL at screening, it decreased from 401 ± 246 pg/mL to 220 ± 209 pg/mL ( p < 0.001) at the end of the study. Among 22 patients with the iPTH level of ≥ 240 pg/mL, 17 achieved the target level. The mean dose of cinacalcet was 41.4 ± 22.2 mg/day and that of etelcalcetide at the end of the study was 6.4 ± 3.7 mg/session in all patients. In 45 patients whose iPTH level was within the management target throughout the study and active vitamin D agent and calcium-based phosphate binder doses were constant, the mean dose of cinacalcet was 45.0 ± 22.4 mg/day and that of etelcalcetide at the end of the study was 6.1 ± 3.1 mg/session. The spKt/V might affect the ratio of etelcalcetide per session to oral cinacalcet per day (45 patients, p = 0.087; 90 patients, p < 0.05) in the generalized linear model. Etelcalcetide-induced severe adverse events were not observed. Conclusions This study reports the conversion dose of etelcalcetide and demonstrates its safety and efficacy in HD patients with SHPT previously treated with cinacalcet. Trial registration UMIN, UMIN000027637 ; Registered on June 5, 2017." @default.
• W3111960933 created "2020-12-21" @default.
• W3111960933 creator A5003409934 @default.
• W3111960933 creator A5003503677 @default.
• W3111960933 creator A5006803779 @default.
• W3111960933 creator A5014579203 @default.
• W3111960933 creator A5022368482 @default.
• W3111960933 creator A5028980723 @default.
• W3111960933 creator A5029841359 @default.
• W3111960933 creator A5029975728 @default.
• W3111960933 creator A5033633458 @default.
• W3111960933 creator A5036970055 @default.
• W3111960933 creator A5039899693 @default.
• W3111960933 creator A5042872942 @default.
• W3111960933 creator A5044766242 @default.
• W3111960933 creator A5045269393 @default.
• W3111960933 creator A5045294195 @default.
• W3111960933 creator A5065963823 @default.
• W3111960933 creator A5068163258 @default.
• W3111960933 creator A5084319945 @default.
• W3111960933 creator A5085942886 @default.
• W3111960933 creator A5087888150 @default.
• W3111960933 creator A5088875207 @default.
• W3111960933 creator A5089324314 @default.
• W3111960933 creator A5091219957 @default.
• W3111960933 date "2020-12-01" @default.
• W3111960933 modified "2023-10-18" @default.
• W3111960933 title "Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial" @default.
• W3111960933 cites W1494926937 @default.
• W3111960933 cites W1973835767 @default.
• W3111960933 cites W1977645780 @default.
• W3111960933 cites W2009529772 @default.
• W3111960933 cites W2015668150 @default.
• W3111960933 cites W2035440905 @default.
• W3111960933 cites W2061394518 @default.
• W3111960933 cites W2090569383 @default.
• W3111960933 cites W2107207648 @default.
• W3111960933 cites W2124526413 @default.
• W3111960933 cites W2151794206 @default.
• W3111960933 cites W2172159264 @default.
• W3111960933 cites W2513830981 @default.
• W3111960933 cites W2571985472 @default.
• W3111960933 cites W2730786221 @default.
• W3111960933 cites W2743323955 @default.
• W3111960933 cites W2792163062 @default.
• W3111960933 cites W2911734644 @default.
• W3111960933 cites W4376848548 @default.
• W3111960933 doi "https://doi.org/10.1186/s41100-020-00310-y" @default.
• W3111960933 hasPublicationYear "2020" @default.
• W3111960933 type Work @default.
• W3111960933 sameAs 3111960933 @default.
• W3111960933 citedByCount "1" @default.
• W3111960933 countsByYear W31119609332021 @default.
• W3111960933 crossrefType "journal-article" @default.
• W3111960933 hasAuthorship W3111960933A5003409934 @default.
• W3111960933 hasAuthorship W3111960933A5003503677 @default.
• W3111960933 hasAuthorship W3111960933A5006803779 @default.
• W3111960933 hasAuthorship W3111960933A5014579203 @default.
• W3111960933 hasAuthorship W3111960933A5022368482 @default.
• W3111960933 hasAuthorship W3111960933A5028980723 @default.
• W3111960933 hasAuthorship W3111960933A5029841359 @default.
• W3111960933 hasAuthorship W3111960933A5029975728 @default.
• W3111960933 hasAuthorship W3111960933A5033633458 @default.
• W3111960933 hasAuthorship W3111960933A5036970055 @default.
• W3111960933 hasAuthorship W3111960933A5039899693 @default.
• W3111960933 hasAuthorship W3111960933A5042872942 @default.
• W3111960933 hasAuthorship W3111960933A5044766242 @default.
• W3111960933 hasAuthorship W3111960933A5045269393 @default.
• W3111960933 hasAuthorship W3111960933A5045294195 @default.
• W3111960933 hasAuthorship W3111960933A5065963823 @default.
• W3111960933 hasAuthorship W3111960933A5068163258 @default.
• W3111960933 hasAuthorship W3111960933A5084319945 @default.
• W3111960933 hasAuthorship W3111960933A5085942886 @default.
• W3111960933 hasAuthorship W3111960933A5087888150 @default.
• W3111960933 hasAuthorship W3111960933A5088875207 @default.
• W3111960933 hasAuthorship W3111960933A5089324314 @default.
• W3111960933 hasAuthorship W3111960933A5091219957 @default.
• W3111960933 hasBestOaLocation W31119609331 @default.
• W3111960933 hasConcept C126322002 @default.
• W3111960933 hasConcept C126894567 @default.
• W3111960933 hasConcept C2775945674 @default.
• W3111960933 hasConcept C2778063415 @default.
• W3111960933 hasConcept C2778838027 @default.
• W3111960933 hasConcept C2780280601 @default.
• W3111960933 hasConcept C2780534505 @default.
• W3111960933 hasConcept C2781208988 @default.
• W3111960933 hasConcept C519063684 @default.
• W3111960933 hasConcept C54847362 @default.
• W3111960933 hasConcept C71924100 @default.
• W3111960933 hasConceptScore W3111960933C126322002 @default.
• W3111960933 hasConceptScore W3111960933C126894567 @default.
• W3111960933 hasConceptScore W3111960933C2775945674 @default.
• W3111960933 hasConceptScore W3111960933C2778063415 @default.
• W3111960933 hasConceptScore W3111960933C2778838027 @default.
• W3111960933 hasConceptScore W3111960933C2780280601 @default.
• W3111960933 hasConceptScore W3111960933C2780534505 @default.
• W3111960933 hasConceptScore W3111960933C2781208988 @default.
• W3111960933 hasConceptScore W3111960933C519063684 @default.
• W3111960933 hasConceptScore W3111960933C54847362 @default.
• W3111960933 hasConceptScore W3111960933C71924100 @default.

• next